[
    [
        {
            "time": "2021-03-26",
            "original_text": "华大基因：两项新冠变异株检测产品获得CE准入资质",
            "features": {
                "keywords": [
                    "华大基因",
                    "新冠变异株",
                    "检测产品",
                    "CE准入资质"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "医疗设备"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因：两项新冠变异株检测产品获得CE准入资质",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]